Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Pimobendan and its effects on life quality
Pimobendan is a very popular drug in dogs. In this brandnew summary its effects on the life quality and survival time in diseases like dilated cardiomyopathy and chronic degenerative valvular disease are studied. Very interesting!

Pimobendan is a novel agent with properties that are highly desirable in the clinical management of congestive heart failure (CHF) secondary to both dilated cardiomyopathy (DCM) and chronic degenerative valvular disease in dogs.

Review of available data suggests that pimobendan is safe, well tolerated, and leads to enhanced quality of life in dogs with CHF secondary to DCM or chronic valvular disease when used in combination with furosemide or other conventional therapies (e.g., angiotensin-converting enzyme inhibitors, digoxin).

Pimobendan leads to a reduction in mortality from CHF associated with DCM, and ongoing studies are evaluating its effects on mortality associated with chronic valvular disease.



Source:
Sonya G. Gordon, Matthew W. Miller, Ashley B. Saunders (2006): Pimobendan in Heart Failure Therapy – A Silver Bullet? In: Journal of the American Animal Hospital Association 42:90-93 (2006)



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Determining the origin of hepatic masses in dogs by CTmembers
Can CT scans diagnose the anatomical origin of hepatic masses? A very interesting question! The objective of this study was to identify CT features of canine hepatic masses that could be used to determine their divisional or lobar origin.

  • Palliative-intent hypofractionated radiotherapy for non-resectable canine thyroid carcinoma
  • High field magnetic resonance imaging to describe soft tissues in the equine stifle
  • Retrobulbar cellulitis and abscessation in dogsmembers
  • Antimicrobial resistance and resistance risk factors in staphylococci isolated from catsmembers
  • Neurological signs after attenuation of single congenital portosystemic shuntsmembers
  • Vocal fold granulomas in brachycephalic dogsmembers
  • Unusual cause of megaoesophagus in three catsmembers
  • First description of a Limy bile syndrome in a dogmembers
  • Novel intratumoral therapy in canine transmissible venereal tumourmembers
  • Long-term outcome of dogs with primary immune-mediated thrombocytopeniamembers
  • Insulin treatment and IGF-I in cats with diabetes mellitusmembers
  • Color doppler ultrasound in neoplastic and non-neoplastic canine testicles members


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved